Brokerages Set Orthofix Medical Inc. (NASDAQ:OFIX) PT at $14.75

Orthofix Medical Inc. (NASDAQ:OFIX) has received a consensus rating of “Hold” from the five analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $14.75.

Several research firms have weighed in on OFIX. Wall Street Zen lowered Orthofix Medical from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Barrington Research boosted their target price on Orthofix Medical from $15.00 to $17.00 and gave the stock an “outperform” rating in a research report on Monday, July 6th. Canaccord Genuity Group lowered their price target on Orthofix Medical from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Orthofix Medical in a research report on Friday, July 17th. Finally, Stifel Nicolaus reduced their price objective on shares of Orthofix Medical from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 22nd.

Insider Buying and Selling

In other Orthofix Medical news, insider Aviva Mcpherron sold 3,670 shares of the stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $9.38, for a total value of $34,424.60. Following the sale, the insider directly owned 66,330 shares in the company, valued at approximately $622,175.40. This trade represents a 5.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.70% of the company’s stock.

Institutional Trading of Orthofix Medical

A number of large investors have recently made changes to their positions in the company. AQR Capital Management LLC lifted its holdings in Orthofix Medical by 67.7% during the first quarter. AQR Capital Management LLC now owns 20,409 shares of the medical device company’s stock worth $333,000 after acquiring an additional 8,241 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Orthofix Medical by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company’s stock worth $335,000 after acquiring an additional 1,213 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Orthofix Medical in the first quarter worth about $1,076,000. Strs Ohio acquired a new stake in shares of Orthofix Medical during the first quarter worth about $150,000. Finally, JPMorgan Chase & Co. raised its position in shares of Orthofix Medical by 15.6% during the second quarter. JPMorgan Chase & Co. now owns 193,549 shares of the medical device company’s stock worth $2,158,000 after purchasing an additional 26,123 shares during the period. Institutional investors own 89.76% of the company’s stock.

Orthofix Medical Stock Performance

OFIX stock opened at $9.79 on Friday. The business’s fifty day moving average is $10.63 and its 200-day moving average is $11.45. The company has a quick ratio of 1.67, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. The company has a market cap of $398.75 million, a P/E ratio of -6.36 and a beta of 0.68. Orthofix Medical has a twelve month low of $8.85 and a twelve month high of $16.99.

Orthofix Medical (NASDAQ:OFIX) last posted its quarterly earnings results on Wednesday, August 5th. The medical device company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.02. Orthofix Medical had a negative return on equity of 14.05% and a negative net margin of 7.41%.The business had revenue of $210.93 million for the quarter, compared to analyst estimates of $209.28 million. Equities research analysts forecast that Orthofix Medical will post -1.29 EPS for the current year.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.